Oslo, Norway, 18 February 2020

Nordic Nanovector ASA (OSE: NANOV) announces its results for the fourth quarter
and full year 2020. A live webcast presentation by Nordic Nanovector's
management team will take place today at 08.30 CET. A link to the webcast and
the presentation is available from the company's homepage
(www.nordicnanovector.com).

Lars Nieba, interim Chief Executive Officer of Nordic Nanovector, commented:
"The company has made significant efforts during 2020 to improve both the
execution of PARADIGME and the chances of a viable regulatory filling outcome.
The progress made, despite the challenging global environment, has been
encouraging and we are pleased to see the enrolment rate into PARADIGME
improving. We remain convinced of the commercial potential of Betalutin® based
on the competitive efficacy data that was seen at the time of the Interim
Analysis and in earlier studies, which could allow it to address an important
unmet need in advanced FL. We continue to work hard to ensure that we complete
PARADIGME in a timely fashion such that we can report preliminary three-month
top-line data in H2'2021."

Q4'2021 Highlights

  · Operational improvements and protocol changes implemented during 2020 have
resulted in a significant recent acceleration in PARADIGME recruitment rate
    · Recruitment rate increased from approx. two patients to approx. five
patients per month despite COVID
    · After the expected lessening of COVID restrictions plus the ongoing
operational improvements, this rate could further increase to at least seven
patients on average per month by late spring
    · 73 patients enrolled as of 17 February 2021 (59 enrolled as of 18 November
2020)
    · 14 patients were enrolled from November 2020 to 17 February 2021 (3
patients from Aug-Nov 2020)

  · Operational improvements that have significantly boosted PARADIGME
recruitment include:
    · Much improved management of the study CRO
    · Appointment of a specialist firm focused on further improving the rate of
recruitment
    · A broadening of the inclusion criteria based on safety data from the
Interim Analysis is estimated to increase the size of the pool of eligible
patients by 30-50%

  · Following interactions with FDA and an internal review, the company believes
that it has clarity on the clinical data set (safety and efficacy) needed to
support a filing at the designated dosing regimen of "40/15" and that this can
be achieved with a reduction of the initially targeted population from 130 to
120 patients
    · On this basis, 47 more patients are required to complete PARADIGME for
regulatory submission of Betalutin®

  · Increased confidence in target of reporting preliminary three-month top-line
data in H2'2021
  · Pipeline update: Final patients enrolled into second safety cohort of Archer
-1 Phase 1 trial of Betalutin® plus rituximab in 2L R/R FL and into LYMRIT 37-05
Phase 1 trial of Betalutin® in patients with DLBCL
    · Preliminary data readouts expected in H1'2021
    · Both trials paused pending analysis of data and evaluation of plans for
further development

  · Results of preclinical studies demonstrating Betalutin® reverses tumour
resistance to rituximab in NHL disease models published in Journal of Nuclear
Medicine

Financial Highlights Q4 and FY'2020

(Figures in brackets = same period 2019 unless otherwise stated)

  · Revenues for the fourth quarter amounted to NOK 0.0 million (NOK 0.0
million). Revenues for the full year 2020 were NOK 0.0 million (NOK 0.0
million).
  · Total operating expenses for the fourth quarter were NOK 106.8 million (NOK
139.3 million). Total operating expenses for the full year 2020 amounted to NOK
434.2 million (NOK 440.4 million).
  · Research and development (preclinical, clinical, medical affairs, regulatory
and CMC activities) expenses accounted for 84 of total operating expenses in
2020 (80 %).
  · Comprehensive loss for the fourth quarter amounted to NOK 112.1 million
(loss of NOK 137.5 million). Comprehensive loss for the full year 2020 was NOK
417.6 million (NOK 433.2 million).
  · Cash and cash equivalents amounted to NOK 294.0 million at the end of
December 2020 (NOK 470.8 million).

Outlook

Nordic Nanovector will continue to focus its resources on completing PARADIGME
and continues to target the preliminary readout of three-month top line data
from PARADIGME in H2'2021.

The company believes that, if positive, these trial data could represent a
significant value inflection point for the company and its shareholders,
confirming Betalutin® as a highly promising new targeted radioimmunotherapy that
can address the unmet needs of R/R FL patients.

The company has streamlined its organisation and taken further steps to conserve
cash. Following the successful private placement in September 2020, Nordic
Nanovector has a cash runway that extends into Q3'2021.

Despite the challenging times, the many positive actions the company has taken
during 2020 have improved the prospects of delivering preliminary readout of
three-month top line data from PARADIGME in H2'2021 although the future impact
of COVID-19 remains uncertain and may still impact the trial timelines. However,
the recent improvements in recruitment pace for PARADIGME, while the COVID-19
pandemic has been severe, are encouraging.

The company also expects the readout of three-month top line data from the
second cohort of the Archer-1 trial and the LYMRIT 37-05 trial in DLBCL in
H1'2021. As stated, the company will assess these data and evaluate its plans
for further development in these important NHL indications.

Presentation and Live Webcast

A live webcast presentation by Nordic Nanovector's management team will take
place today at 08.30 CET. The webcast can be accessed from
www.nordicnanovector.com in the section: Investors & Media and a recording will
also be available on this page after the event.

The results report and the presentation will be available at
www.nordicnanovector.com in the section: Investors & Media/Reports and
Presentation/Interim Reports/2020 from 7:00am CET the same day

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.